| Name | Cysteamine hydrochloride |
| Description | Cysteamine hydrochloride is an orally administered small-molecule drug commonly used for the treatment of nephropathic cystinosis. It also functions as an antioxidant and is used in experimental studies to induce gastrointestinal disorders, duodenal ulcers, and kidney injury models in mice. |
| In vitro | Cysteamine enhances intracellular glutathione (GSH) levels in cystinotic cells, effectively restoring their altered redox state and demonstrating antioxidant capabilities by increasing glutathione production, thus scavenging harmful OH and HOCl. It also mitigates increased apoptosis rates in cystinotic cells by counteracting the effects of elevated caspase 3 and protein kinase Cε activity. Furthermore, Cysteamine boosts the production of various heat shock proteins (HSP), notably murine Hsp40. It exhibits a dose-dependent mitigation of doxorubicin-induced death in cancer cells, including HeLa and B16 cells, without affecting cell survival on its own. Remarkably, it enhances the efficacy of doxorubicin in doxorubicin-resistant breast cancer cells, significantly increasing cell death. Additionally, Cysteamine (100 μM) not only heightens intracellular GSH levels but also improves the development of matured oocytes to the blastocyst stage in embryo cultures. [1][2] |
| In vivo | Cysteamine is introduced as a treatment for cystinosis by depleting lysosomal cystine. Cystamine can inhibit transglutaminase activity by binding to the cysteine in its active center. Cysteamine increases brain levels of brain-derived neurotrophic factor (BDNF), which is caused by the increased expression of the heat shock DNAJ-containing protein 1 (HSJ1). Cysteamine inhibits the formation of gastric and mammary tumors that are induced chemically or after irradiation, respectively. The administration of Cysteamine is also able to inhibit the metastasis of pancreatic cancer in a mouse model by decreasing the expression and activity of metalloproteinases. [1] |
| Storage | store under nitrogen | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | Ethanol : 22 mg/mL (193.64 mM), Sonication is recommended.
H2O : 21 mg/mL (184.84 mM), Sonication is recommended.
10% DMSO+40% PEG300+5% Tween 80+45% Saline : 2 mg/mL (17.6 mM), Sonication is recommended.
DMSO : 175 mg/mL (1540.36 mM), Sonication is recommended.
|
| Keywords | ReactiveOxygenSpecies | Reactive Oxygen Species | orally | nephropathic | Inhibitor | inhibit | EndogenousMetabolite | Endogenous Metabolite | cystinosis | Cysteamine hydrochloride | Cysteamine Hydrochloride | Cysteamine | b-Mercaptoethylamine Hydrochloride | beta-Mercaptoethylamine Hydrochloride | Autophagy | Apoptosis | antioxidant | 2-Mercaptoethylamine | 2-Aminoethanethiol |
| Inhibitors Related | Sucrose | Stavudine | Hydroxychloroquine | Daidzein | Tributyrin | Ferulic Acid | Paeonol | Glycerol | Thymidine | Naringin | Alginic acid | 3-Indoleacetic acid |
| Related Compound Libraries | Bioactive Compound Library | Natural Product Library | Anti-Viral Compound Library | Drug Repurposing Compound Library | Natural Product Library for HTS | FDA-Approved Drug Library | Cosmetic Ingredient Compound Library | Anti-Aging Compound Library | Human Endogenous Metabolite Library | Immunology/Inflammation Compound Library | Bioactive Compounds Library Max | Anti-Cancer Drug Library |
United States
